141 related articles for article (PubMed ID: 20881577)
1. Mitotic count, brain invasion, and location are independent predictors of recurrence-free survival in primary atypical and malignant meningiomas: a study of 86 patients.
Vranic A; Popovic M; Cör A; Prestor B; Pizem J
Neurosurgery; 2010 Oct; 67(4):1124-32. PubMed ID: 20881577
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathologic features of aggressive meningioma emphasizing the role of radiotherapy in treatment.
Engenhart-Cabillic R; Farhoud A; Sure U; Heinze S; Henzel M; Mennel HD; Bertalanffy H
Strahlenther Onkol; 2006 Nov; 182(11):641-6. PubMed ID: 17072521
[TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
4. Atypical and malignant meningioma: outcome and prognostic factors in 119 irradiated patients. A multicenter, retrospective study of the Rare Cancer Network.
Pasquier D; Bijmolt S; Veninga T; Rezvoy N; Villa S; Krengli M; Weber DC; Baumert BG; Canyilmaz E; Yalman D; Szutowicz E; Tzuk-Shina T; Mirimanoff RO;
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1388-93. PubMed ID: 18294779
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
6. Sensitivity and usefulness of anti-phosphohistone-H3 antibody immunostaining for counting mitotic figures in meningioma cases.
Fukushima S; Terasaki M; Sakata K; Miyagi N; Kato S; Sugita Y; Shigemori M
Brain Tumor Pathol; 2009; 26(2):51-7. PubMed ID: 19856215
[TBL] [Abstract][Full Text] [Related]
7. Immunohistochemical expression of cathepsin D in meningiomas.
Castilla EA; Prayson RA; Abramovich CM; Cohen ML
Am J Clin Pathol; 2003 Jan; 119(1):123-8. PubMed ID: 12520707
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic validity of the Ki-67 labeling index using the MIB-1 monoclonal antibody in the grading of meningiomas.
Devaprasath A; Chacko G
Neurol India; 2003 Sep; 51(3):336-40. PubMed ID: 14652433
[TBL] [Abstract][Full Text] [Related]
9. Relationship between malignant subtypes of meningioma and clinical outcome.
Ko KW; Nam DH; Kong DS; Lee JI; Park K; Kim JH
J Clin Neurosci; 2007 Aug; 14(8):747-53. PubMed ID: 17499508
[TBL] [Abstract][Full Text] [Related]
10. Prognostic significance of the mitotic index using the mitosis marker anti-phosphohistone H3 in meningiomas.
Kim YJ; Ketter R; Steudel WI; Feiden W
Am J Clin Pathol; 2007 Jul; 128(1):118-25. PubMed ID: 17580279
[TBL] [Abstract][Full Text] [Related]
11. Surgery for convexity meningiomas.
Morokoff AP; Zauberman J; Black PM
Neurosurgery; 2008 Sep; 63(3):427-33; discussion 433-4. PubMed ID: 18812953
[TBL] [Abstract][Full Text] [Related]
12. [Proliferative markers of meningiomas: immunohistochemical analysis and prognostic value].
Korshunov AG; Shishkina LV; Golanov AV
Arkh Patol; 2002; 64(1):29-33. PubMed ID: 11889696
[TBL] [Abstract][Full Text] [Related]
13. Proliferation and progesterone receptor status in benign meningiomas are not age dependent.
Roser F; Nakamura M; Ritz R; Bellinzona M; Dietz K; Samii M; Tatagiba MS
Cancer; 2005 Aug; 104(3):598-601. PubMed ID: 15952201
[TBL] [Abstract][Full Text] [Related]
14. Primary resected meningiomas: relapses and proliferation markers.
Kalala JP; Caemaert J; De Ridder L
In Vivo; 2004; 18(4):411-6. PubMed ID: 15369177
[TBL] [Abstract][Full Text] [Related]
15. The Ki-67 proliferation antigen in meningiomas. Experience in 600 cases.
Roser F; Samii M; Ostertag H; Bellinzona M
Acta Neurochir (Wien); 2004 Jan; 146(1):37-44; discussion 44. PubMed ID: 14740263
[TBL] [Abstract][Full Text] [Related]
16. The prognostic significance of MIB-1, p53, and DNA flow cytometry in completely resected primary meningiomas.
Perry A; Stafford SL; Scheithauer BW; Suman VJ; Lohse CM
Cancer; 1998 Jun; 82(11):2262-9. PubMed ID: 9610708
[TBL] [Abstract][Full Text] [Related]
17. Meningiomas: loss of heterozygosity on chromosome 10 and marker-specific correlations with grade, recurrence, and survival.
Mihaila D; Jankowski M; Gutiérrez JA; Rosenblum ML; Newsham IF; Bögler O; Rempel SA;
Clin Cancer Res; 2003 Oct; 9(12):4443-51. PubMed ID: 14555517
[TBL] [Abstract][Full Text] [Related]
18. Brain Invasion in Meningiomas: Incidence and Correlations with Clinical Variables and Prognosis.
Spille DC; Heß K; Sauerland C; Sanai N; Stummer W; Paulus W; Brokinkel B
World Neurosurg; 2016 Sep; 93():346-54. PubMed ID: 27344043
[TBL] [Abstract][Full Text] [Related]
19. Primary ear and temporal bone meningiomas: a clinicopathologic study of 36 cases with a review of the literature.
Thompson LD; Bouffard JP; Sandberg GD; Mena H
Mod Pathol; 2003 Mar; 16(3):236-45. PubMed ID: 12640104
[TBL] [Abstract][Full Text] [Related]
20. AKT2 expression in histopathologic grading and recurrence of meningiomas.
Wang Q; Fan SY; Qian J; Wang JY; Lu YC; Hu GH; Luo C
Eur J Surg Oncol; 2014 Sep; 40(9):1056-61. PubMed ID: 24656454
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
